Takeda sells four diabetes products to Teijin Pharma for $1.25B

 Takeda Pharmaceutical Co said on Friday it agreed to sell four diabetes products in Japan to Teijin Pharma Ltd for 133 billion yen ($1.25 billion).

Takeda will sell the Japanese marketing rights of drugs Nesina, Liovel, Inisync and Zafatek to Teijin Pharma subject to regulator approval, the company said in a release. The drugs generated 30.8 billion yen in sales in fiscal 2019, Takeda said.

The sale is the latest in a series of deals that Takeda has undertaken to reduce debt and refocus its business after its purchase of Shire Ltd, which was completed in January 2019.

https://www.reuters.com/article/us-takeda-diabetes-sale/japans-takeda-sells-four-diabetes-products-to-teijin-pharma-for-1-25-billion-idUSKBN2AQ10Y